Two studies showed the vaccine to be more than 95 percent effective at protecting against severe disease or death from the variants first identified in South Africa and the U.K.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.